专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006057912A3 RASAGILINE ORALLY DISINTEGRATING COMPOSITIONS 审中-公开
标题翻译： RASAGILINE ORAZY DISINTEGRATING组合物
公开(公告)号：WO2006057912A3
公开(公告)日：2006-08-17
申请号：PCT/US2005041882
申请日：2005-11-17
申请人： TEVA PHARMA , TEVA PHARMA , PATASHNIK SHULAMIT , LICHT DANIELLA , GILBERT ADRIAN
发明人： PATASHNIK SHULAMIT , LICHT DANIELLA , GILBERT ADRIAN
IPC分类号： A61K31/135
CPC分类号： A61K9/0056 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K31/135 , A61K31/4166
摘要： This invention provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, a mixture of a disintegrant, a flow agent and particles having a non-filamentous microstructure of at least two sugar alcohols, a supplemental sugar alcohol, a supplemental flow agent, and a supplemental disintegrant. This invention further provides a method of treating a subject afflicted with Parkinson's disease comprising administering to the subject a therapeutically effective amount of the solid pharmaceutical composition, thereby treating the subject. Finally, this invention provides a process of making such solid pharmaceutical compositions.
摘要翻译：本发明提供了包含雷沙吉兰或雷沙吉兰药学上可接受的盐的固体药物组合物，以及具有至少两种糖醇的非丝状微观结构的颗粒。本发明还提供了一种固体药物组合物，其包含雷沙吉兰或雷沙吉兰药学上可接受的盐，崩解剂，流动剂和具有至少两种糖醇的非丝状微结构的颗粒，补充糖醇，辅助流药剂和补充崩解剂。本发明进一步提供了治疗患有帕金森氏病的受试者的方法，包括给予受试者治疗有效量的固体药物组合物，从而治疗受试者。最后，本发明提供了制备这种固体药物组合物的方法。

2. 发明专利

IL183236A Solid pharmaceutical composition of rasagiline 未知
公开(公告)号：IL183236A
公开(公告)日：2014-03-31
申请号：IL18323607
申请日：2007-05-15
申请人： TEVA PHARMA , GILBERT ADRIAN , LICHT DANIELLA , PATASHNIK SHULAMIT
发明人： GILBERT ADRIAN , LICHT DANIELLA , PATASHNIK SHULAMIT

3. 发明专利

IL195724A Stable laquinimod preparations 未知
公开(公告)号：IL195724A
公开(公告)日：2015-09-24
申请号：IL19572408
申请日：2008-12-04
申请人： TEVA PHARMA , LICHT DANIELLA , PATASHNIK SHULAMIT , GILBERT ADRIAN
发明人： LICHT DANIELLA , PATASHNIK SHULAMIT , GILBERT ADRIAN
IPC分类号： A61K20060101 , A61P20060101
摘要： The invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable salt of N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, N-methylglucamine, and a pharmaceutically acceptable carrier.

4. 发明申请

WO03005967A3 DUAL RELEASE LEVODOPA ETHYL ESTER AND DECARBOXYLASE IN CONTROLLED RELEASE CORE 审中-公开
标题翻译：控制释放核心中的双释放乙醇醚和脱羧酶
公开(公告)号：WO03005967A3
公开(公告)日：2003-09-04
申请号：PCT/US0222206
申请日：2002-07-12
申请人： TEVA PHARMA , TEVA PHARMA , LICHT DANIELA , PATASHNIK SHULAMIT , NAFTALI EZMIRA , SAYAG NAIM , GILBERT ADRIAN , COHEN SASSON , ZOLLMANN CORINNE
发明人： LICHT DANIELA , PATASHNIK SHULAMIT , NAFTALI EZMIRA , SAYAG NAIM , GILBERT ADRIAN , COHEN SASSON , ZOLLMANN CORINNE
IPC分类号： A61K9/20 , A61K9/22 , A61K9/24 , A61K9/26 , A61K31/198 , A61K45/06 , A61P25/16
CPC分类号： A61K45/06 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/209 , A61K31/198 , A61K2300/00
摘要： A tablet which comprises: an inner core formulated for controlled release comprising a mixture of (a) a granulated admixture of a decarboxylase inhibitor and a surfactant, and (b) levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof; and an outer layer encapsulating the inner core and formulated for immediate release comprising a mixture of a granulated decarboxylase inhibitor and levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof. The subject invention also encompasses a method of treating patients suffering from Parkinson's disease or related disorders by the administration of the pharmaceutical compositions of the subject invention. Additionally, the subject invention provides methods of manufacturing the tablets of the subject invention.
摘要翻译：一种片剂，其包含：配制用于控释的内核，其包含（a）脱羧酶抑制剂和表面活性剂的颗粒状混合物的混合物，和（b）左旋多巴乙酯或其衍生物或药学上可接受的盐; 以及包封内核并配制成立即释放的外层，其包含粒状脱羧酶抑制剂和左旋多巴乙酯或其衍生物或药学上可接受的盐的混合物。本发明还包括通过施用本发明的药物组合物治疗患有帕金森病或相关病症的患者的方法。另外，本发明提供了制造本发明的片剂的方法。

5. 发明申请

WO03005968A2 DUAL RELEASE FORMULATION COMPRISING LEVODOPA ETHYL ESTER AND A DECARBOXYLASE INHIBITOR IN AN IMMEDIATE-RELEASE LAYER WITH LEVODOPAETHYL ESTER IN A CONTROLLED RELEASE CORE 审中-公开
标题翻译：在释放出的核心内含有左旋乙酸酯的立即释放层中的双酚A乙酯和脱羧酶抑制剂的双重释放配方
公开(公告)号：WO03005968A2
公开(公告)日：2003-01-23
申请号：PCT/US0222207
申请日：2002-07-12
申请人： TEVA PHARMA , TEVA PHARMA , LICHT DANIELA , PATASHNIK SHULAMIT , NAFTALI EZMIRA , SAYAG NAIM , GILBERT ADRIAN , COHEN SASSON , ZOLLMANN CORINNE
发明人： LICHT DANIELA , PATASHNIK SHULAMIT , NAFTALI EZMIRA , SAYAG NAIM , GILBERT ADRIAN , COHEN SASSON , ZOLLMANN CORINNE
IPC分类号： A61K9/20 , A61K9/22 , A61K9/24 , A61K9/26 , A61K31/198 , A61K45/06 , A61P25/16 , A61K
CPC分类号： A61K45/06 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/209 , A61K31/198 , A61K2300/00
摘要： A tablet which comprises an inner core formulated for controlled release consisting essentially of a mixture of levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof, a carrier and an inner core excipient; and an outer layer encapsulating the inner core and formulated for immediate release comprising a mixture of a decarboxylase inhibitor and levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof. The subject invention also encompasses a method of treating patients suffering from Parkinson's disease or related disorders by the administration of the pharmaceutical compositions of the subject invention. The subject invention also provides methods of manufacturing the tablets of the subject invention.
摘要翻译：一种片剂，其包含配制成用于控释的内核，其主要由左旋多巴乙酯或其衍生物或其药学上可接受的盐，载体和内核赋形剂的混合物组成; 以及封装内核并配制成立即释放的外层，其包含脱羧酶抑制剂和左旋多巴乙酯或其衍生物或药学上可接受的盐的混合物。本发明还包括通过施用本发明的药物组合物治疗患有帕金森病或相关病症的患者的方法。本发明还提供了制备本发明的片剂的方法。

6. 发明申请

WO2004071424A3 IMMEDIATE RELEASE FORMULATION OF N<->(2<->PROPYLPENTANOYL)GLYCINAMIDE 审中-公开
标题翻译：立即释放N - （2 - 丙酰胺）甘氨酰胺的配方
公开(公告)号：WO2004071424A3
公开(公告)日：2005-02-24
申请号：PCT/US2004003346
申请日：2004-02-05
申请人： TEVA PHARMA , TEVA PHARMA , LICHT DANIELLA , ABD-ELHAI SUHER , COHEN RACHEL , DAGAN-LION MAZZI , GILBERT ADRIAN , LEIBOVITCH NOA , COHEN SASSON , LEVY RUTH
发明人： LICHT DANIELLA , ABD-ELHAI SUHER , COHEN RACHEL , DAGAN-LION MAZZI , GILBERT ADRIAN , LEIBOVITCH NOA , COHEN SASSON , LEVY RUTH
IPC分类号： A61K20060101 , A61K9/20 , A61K31/16 , A61K31/19
CPC分类号： A61K31/16 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K31/19
摘要： The subject invention provides an immediate release tablet comprising the following components: a) a uniform admixture of an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure: wherein R1, R2, and R3 are independently the same or different and are hydrogen, a C1-C6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3; and a hydroxypropyl cellulose, and b) a disintegrant, a process for manufacturing the tablet and a method of treating neuropathic pain, epilepsy, mania in bipolar disorder, a headache disorder, pain or of effecting pain prophylaxis in a subject.
摘要翻译：本发明提供了包含以下组分的速释片剂：a）选自丙戊酸钠，丙戊酸的药学上可接受的盐或酯，二价丙磺酸钠，valpromide和具有下列成分的化合物的活性成分的均匀混合物：结构式：其中R1，R2和R3独立地相同或不同，为氢，C1-C6烷基，芳烷基或芳基，n为大于或等于0的整数，小于或等于3; 和羟丙基纤维素，以及b）崩解剂，制造片剂的方法以及治疗受试者中的神经性疼痛，癫痫，躁狂症，双相情感障碍，头痛症，疼痛或疼痛预防的方法。

7. 发明申请

WO2004071421A3 SUSTAINED RELEASE FORMULATION OF N-(2-PROPYLPENTANOYL) GLYCINAMIDE AND RELATED COMPOUNDS 审中-公开
标题翻译： N-（2-丙酰氨基）甘氨酰胺及相关化合物的持续释放配方
公开(公告)号：WO2004071421A3
公开(公告)日：2004-11-18
申请号：PCT/US2004003281
申请日：2004-02-05
申请人： TEVA PHARMA , TEVA PHARMACEUTICAL USA INC , LICHT DANIELLA , LOVINGER IOANA , ABD-ELHAI SUHER , DAGAN-LION MAZZI , GILBERT ADRIAN , LEIBOVITCH NOA , COHEN SASSON , LEVY RUTH
发明人： LICHT DANIELLA , LOVINGER IOANA , ABD-ELHAI SUHER , DAGAN-LION MAZZI , GILBERT ADRIAN , LEIBOVITCH NOA , COHEN SASSON , LEVY RUTH
IPC分类号： A61K9/20 , A61K9/22 , A61K31/16 , A61K31/19
CPC分类号： A61K31/16 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K31/19
摘要： The subject provides a sustained release tablet comprising the following components: a) a uniform admixture of an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure of formula (I) or formula (II), wherein R1, R2, and R3 are independently the same or different and are hydrogen, a C1-C6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3; and a binder, and b) a hydroxypropylmethyl cellulose, a process for manufacturing the tablet and a method of treating neuropathic pain, epilepsy, mania in bipolar disorder, a headache disorder, pain or of effecting pain prophylaxis in a subject.
摘要翻译：受试者提供了包含以下组分的持续释放片剂：a）选自丙戊酸钠，丙戊酸的药学上可接受的盐或酯，二价丙磺酸钠，valpromide和具有下列成分的化合物的活性成分的均匀混合物：式（I）或式（II）的结构，其中R 1，R 2和R 3独立地相同或不同，为氢，C 1 -C 6烷基，芳烷基或芳基，n为整数大于或等于0且小于或等于3; 和粘合剂，以及b）羟丙基甲基纤维素，制备片剂的方法以及治疗神经性疼痛，癫痫，双相情感障碍中的躁狂症，头痛障碍，疼痛或对受试者进行疼痛预防的方法。

8. 发明申请

WO2004064787A3 PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS 审中-公开
标题翻译：用于治疗系统性红斑狼疮的肽的配体配方
公开(公告)号：WO2004064787A3
公开(公告)日：2005-12-15
申请号：PCT/US2004000948
申请日：2004-01-14
申请人： TEVA PHARMA , TEVA PHARMA , COHEN-VERED SHARON , NAFTALI ESMIRA , WEINSTEIN VERA , GILBERT ADRIAN , KLINGER ETY
发明人： COHEN-VERED SHARON , NAFTALI ESMIRA , WEINSTEIN VERA , GILBERT ADRIAN , KLINGER ETY
IPC分类号： A61K20060101 , A61K6/00 , A61K9/00 , A61K9/19 , A61K38/00 , A61K38/08 , A61K38/10 , A61K38/16 , A61K38/17 , A61K39/395 , A61K47/40 , A61P37/00 , C07K7/06 , C07K7/08 , C07K14/47
CPC分类号： C07K7/06 , A61K9/0019 , A61K9/19 , A61K38/1709 , C07K7/08 , C07K14/4713 , C07K2319/00
摘要： The subject invention provides a pharmaceutical composition comprising: an, aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a) peptide comprising at least 12 and at most 30 consecutive amino acids having a sequence corresponding to (i) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a human monoclonal anti-DNA 16/6 Id antibody, or (ii) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a pathogenic anti-DNA monoclonal antibody that induces a systemic lupus erythematosus (SLE)-like disease response in mice, or b) a peptide comprising consecutive amino acids having the sequence shown by any of SEQ ID NOS. 8-17, or c) a peptide comprising consecutive amino acids having a sequence of any of and b), or at least two of the sequences in (a)(1), (a) (ii) and (b)(i) through (b)(x), or d) a peptide comprising consecutive amino acids having a sequence comprising at least two identical sequences included in (a) (i), (a) (ii) and (b) (i) through (b)(x); and a solubility enhancer, wherein both the peptide and the solubility enhancer are dissolved in the aqueous carrier; and wherein the composition has a pH between 4 and 9, and a method of alleviating symptoms of SLE in a human by administering an effective amount of the composition.
摘要翻译：本发明提供药物组合物，其包含：水性载体; 包含至少12个和至多30个连续氨基酸的a）肽的药学上可接受的盐的0.1mg / ml至20mg / ml的组合物，其具有对应于（i）互补序列中发现的氨基酸序列的序列确定人单克隆抗-DNA 16/6 Id抗体的重链或轻链的确定区（CDR），或（ii）在重或偶联抗体的互补决定区（CDR）内发现的氨基酸序列在小鼠中诱导系统性红斑狼疮（SLE）样疾病反应的致病性抗-DNA单克隆抗体的轻链，或b）包含具有SEQ ID NOS中任一个所示序列的连续氨基酸的肽。（a）（1），（a）（ii）和（b）（i）中的至少两个序列的连续氨基酸的肽，）通过（b）（x），或d）包含连续氨基酸的肽，其具有包含（a）（i），（a）（ii）和（b）（i）至（b）（X）; 和溶解度增强剂，其中肽和溶解度增强剂都溶解在水性载体中; 并且其中所述组合物的pH为4至9，以及通过施用有效量的组合物来减轻人类SLE症状的方法。

9. 发明申请

WO2004064788A3 PARENTERAL FORMULATIONS OF A PEPTIDE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS 审中-公开
标题翻译：用于治疗系统性红斑狼疮的肽的配体配方
公开(公告)号：WO2004064788A3
公开(公告)日：2005-03-24
申请号：PCT/US2004000955
申请日：2004-01-14
申请人： TEVA PHARMA , TEVA PHARMA , COHEN-VERED SHARON , NAFTALI ESMIRA , WEINSTEIN VERA , GILBERT ADRIAN , KLINGER ETY
发明人： COHEN-VERED SHARON , NAFTALI ESMIRA , WEINSTEIN VERA , GILBERT ADRIAN , KLINGER ETY
IPC分类号： A61K20060101 , A61K9/00 , A61K9/19 , A61K31/724 , A61K38/00 , A61K38/10 , A61K39/00 , A61K39/38 , A61K47/40 , A61K47/48 , A61K51/10
CPC分类号： B82Y5/00 , A61K9/0019 , A61K9/19 , A61K31/724 , A61K38/10 , A61K47/6951 , A61K2300/00
摘要： The subject invention provides a pharmaceutical composition comprising an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a peptide having the structural formula NH2-Gly Tyr Tyr Tip Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-cooH; and a substituted 13-cyclodextrin in an amount effective to dissolve the peptide in the aqueous carrier, wherein the composition ha.s a pH between 4 and 9, a process for preparation, and a method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject the pharmaceutical composition.
摘要翻译：本发明提供包含水性载体的药物组合物; 从0.1mg / ml至20mg / ml组合物的具有结构式NH 2 -Gly Tyr Tyr Tip Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-cooH的药学上可接受的盐; 和有效溶解水的载体中的肽的取代的13-环糊精，其中组合物的pH为4〜9，制备方法和缓解系统性红斑狼疮（SLE）症状的方法人受试者包括向人受试者施用药物组合物。

10. 发明申请

WO2006091836A9 FORMULATIONS OF LADOSTIGIL TARTRATE 审中-公开
标题翻译：抗坏血酸盐配方
公开(公告)号：WO2006091836A9
公开(公告)日：2006-10-26
申请号：PCT/US2006006636
申请日：2006-02-24
申请人： TEVA PHARMA , TEVA PHARMA
发明人： LIGHT DANIELLA , LOVINGER IOANA , CACIULARU FANNY , GILBERT ADRIAN
IPC分类号： A61K31/165
CPC分类号： A61K31/165 , A61K9/1623 , A61K9/1652 , A61K9/2018 , A61K9/2059 , A61K31/27 , A61K31/325
摘要： Disclosed are formulations of ladostigil tartrate, including pharmaceutical compositions, process for the manufacture, and use thereof.
摘要翻译：本发明公开了酒石酸放射剂，包括药物组合物，制造方法和使用方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式